Non‐small cell lung cancer in China

P Chen, Y Liu, Y Wen, C Zhou - Cancer Communications, 2022 - Wiley Online Library
In China, lung cancer is a primary cancer type with high incidence and mortality. Risk factors
for lung cancer include tobacco use, family history, radiation exposure, and the presence of …

Tyrosine kinase inhibitors for solid tumors in the past 20 years (2001–2020)

L Huang, S Jiang, Y Shi - Journal of hematology & oncology, 2020 - Springer
Tyrosine kinases are implicated in tumorigenesis and progression, and have emerged as
major targets for drug discovery. Tyrosine kinase inhibitors (TKIs) inhibit corresponding …

[HTML][HTML] The role of VEGF in cancer-induced angiogenesis and research progress of drugs targeting VEGF

S Ghalehbandi, J Yuzugulen, MZI Pranjol… - European Journal of …, 2023 - Elsevier
Angiogenesis is a double-edged sword; it is a mechanism that defines the boundary
between health and disease. In spite of its central role in physiological homeostasis, it …

Emerging therapies for small cell lung cancer

S Yang, Z Zhang, Q Wang - Journal of hematology & oncology, 2019 - Springer
Currently, chemotherapy remains the standard treatment for first-and second-line
management of small cell lung cancer (SCLC). Immunotherapy has made progress in the …

[HTML][HTML] Phase 1b study of sintilimab plus anlotinib as first-line therapy in patients with advanced NSCLC

T Chu, R Zhong, H Zhong, BO Zhang, W Zhang… - Journal of Thoracic …, 2021 - Elsevier
Introduction Although the interaction between tumor immune microenvironment and
angiogenesis has been well established, evidence supporting the chemo-free combination …

Recent advances on anti-angiogenesis receptor tyrosine kinase inhibitors in cancer therapy

S Qin, A Li, M Yi, S Yu, M Zhang, K Wu - Journal of hematology & oncology, 2019 - Springer
Angiogenesis has always been the topic of major scientific interest in the field of malignant
tumors. Nowadays, targeting angiogenesis has achieved success in various carcinomas by …

Immune checkpoint inhibitors in non-small cell lung cancer: progress, challenges, and prospects

S Tang, C Qin, H Hu, T Liu, Y He, H Guo, H Yan… - Cells, 2022 - mdpi.com
Non-small cell lung cancer is one of the most common types of malignances worldwide and
the main cause of cancer-related deaths. Current treatment for NSCLC is based on surgical …

[HTML][HTML] Cancer cells co-opt nociceptive nerves to thrive in nutrient-poor environments and upon nutrient-starvation therapies

Y Zhang, C Lin, Z Liu, Y Sun, M Chen, Y Guo, W Liu… - Cell metabolism, 2022 - cell.com
Although nutrient-starvation therapies can elicit strong anti-tumor effects in multiple
carcinomas, it has been convincingly demonstrated that cancer cells exploit the tumor …

MET inhibitors for targeted therapy of EGFR TKI-resistant lung cancer

Q Wang, S Yang, K Wang, SY Sun - Journal of hematology & oncology, 2019 - Springer
Abstract Treatment of non-small cell lung cancer (NSCLC) harboring epidermal growth
factor receptor (EGFR) activating mutation with EGFR-TKIs has achieved great success, yet …

Inhibition of FGF‐FGFR and VEGF‐VEGFR signalling in cancer treatment

G Liu, T Chen, Z Ding, Y Wang, Y Wei, X Wei - Cell proliferation, 2021 - Wiley Online Library
The sites of targeted therapy are limited and need to be expanded. The FGF‐FGFR
signalling plays pivotal roles in the oncogenic process, and FGF/FGFR inhibitors are a …